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INTRODUCTION
The incidence of pneumonia may vary greatly
in a given
herd. Death loss is frequently high and surviving
animals may
be affected with chronic bronchopneumonia.
Treatment of
bovine bronchopneumonia is difficult and frequently
unsuccess-
ful.
The time interval for an animal to pass from
the acute
stage of bronchopneumonia to the chronic stage of
broncho-
pneumonia may be as short as seven days (Leipold, 1977).
This
short interval may challenge the efficacy of
treatment, even
if the causative bacteria is sensitive to the
chemotherapeutic
agent.
A common histopathological finding in chronic
broncho-
pneumonia is the occlusion of the lumen of the alveoli,
bronchioles, and bronchi due to an exudate accumulation.
The
exudate, composed of mucus, bacteria, neutrophils, macrophages,
and blood (Jensen et al. 1976) , limits the activity of the
mucociliary apparatus by limiting the amount of oxygen reach-
ing the alveolar epithelium. The resulting pulmonary
hypoxia
impairs pulmonary clearance and macrophage function (Leak,
1964 and Stossel, 1974). In addition, the accumulated exudate
protects bacteria from normally secreted respiratory immuno-
globulins (Dulfano, 1973) and antibacterial agents.
Prompt elimination of tracheobronchial secretions may
prevent the development of serious pulmonary complications
in the patient with inflammation of the respiratory passage
(Thomas and Treasure, 1977). Conventional treatment of
pneumonia with antibacterial agents have little or no effect
on this common sequella to bovine bronchopneumonia. The
benefit of aerosol therapy as an adjunct to conventional
treatment is promising. The administration of antibacterial
agents and mucolytic agents by nebulization through indwelling
tracheal catheters will allow such agents to penetrate the
obstructed bronchioles and alveoli of the lungs and to
possibly minimize the pulmonary changes that are seen in
chronic bronchopneumonia.
This study was undertaken to investigate the additive
effect of aerosolized antibacterial and mucolytic agents, in
conjunction, with the conventional treatment of bovine
bronchopneumonia. The primary purpose of the study was to
evaluate the clinical response of bovine subjects affected
with acute bronchopneumonia.
REVIEW OF THE LITERATURE
Miller (1973) reviewed the use of inhalation therapy and
found it dated back to the oldest written medical history.
Presently, the therapeutic use of inhaled aerosols is recognized
as an essential part of the total approach for the treatment
of a wide variety of acute and chronic respiratory disorders
in man. In man, aerosol therapy has been used in asthma,
bronchitis, bronchiolitis, emphysema, cystic fibrosis, alveolar
proteinosis, bronchopneumonia, and also to relieve broncho-
spasm, decrease mucosal edema, and to liquefy bronchial
secretions.
Lourenco (1974) states that because of the large surface
area of the lung and because of accessibility, the respiratory
tract is ideal for treatment with aerosols. It is difficult
to measure the exact location where an aerosol will exert its
activity. Lourenco (1974) also states that theoretical
models have been designed to determine distribution of parti-
cles, but individual patient variance, disease alteration of
respiratory pathways, and bronchospasm make it impossible to
predict the site of pulmonary deposition of a therapeutic
aerosol.
Miller (1974) concludes that because aerosols are deliv-
ered best to the well-ventilated areas of the lung it is
necessary to provide improved ventilation if antibiotic
aerosols are to be delivered to diseased areas. Postural
drainage, deep breathing, chest percussion and/or endotracheal
suction may improve ventilation.
Miller (1973) outlined the spectrum of aerosol therapy
established for man. Aerosol distribution and deposition,
particle size and potential toxicity affects the method of
aerosol therapy. This may be summarized to include the
following:
1. Deposition of relatively minuscule amounts of very
potent agents in smaller airways obtains optimal
topical therapeutic effect with minimal systemic side
effects. Particle droplet size is 0.3 microns to
3.0 microns.
2. Deposition of moderate amounts of certain agents where
a topical effect is desired or where the agent is
effective topically only avoids otherwise potentially
toxic systemic effects. Particle size range is small
enough to penetrate yet large enough to carry an
effective volume of medication, approximately 1 micron
to 20 microns.
3. Deposition of relatively large amounts of bland
substances in the medium and large airways promoting
bronchial evacuation with minimal mucosal irritation.
Particle size range is 5 microns to 40 microns.
4. Humidification of the inspired air is done with large
particles (greater than 10 microns) of water as
heated or unheated mist.
When therapy is to be directed to the lower airways, a
mouthpiece or at least breathing through the mouth with a mask
should be the method of choice taking care to keep the teeth
and tongue out of the path of the aerosol. Nasal breathing
will cause more than 95 percent of the aerosol to be deposited
in the nose.
Morrow (197 4) reviewed therapeutic particle size and
stated that for therapeutic and diagnostic aerosols, particles
need to be in the aerodynamic size range of 1-10 microns in
diameter. Particles of this size range were easily produced,
sufficiently stable aerosols, and massive enough to deposit
and deliver the requisite amount of drug or agent. To include
the alveolated regions of the lungs, the particle size range
should be restricted to the 1 to 5 micron diameter.
Veit (1976) illustrated particle distribution and pene-
tration of the normal bovine lung. The upper airway anterior
to the larynx contained particles of all sizes, but especially
those over 10 microns. Larger particles were removed by the
mucociliary apparatus and turbinates. As air passes into the
trachea the maximum particle size was reduced to 5-10 microns
throughout the trachea. Particle size in the primary bronchi
was in the range of 1-3 microns with few particles above 5
microns. Alveolar tissue was only penetrated by particles in
the size range of 1-2 microns.
Bolton (1977) described the principals of aerosol therapy
in small animal medicine and discussed particle size and
stability. Larger particles (greater than 5 to 10 microns)
were deposited in the upper airways. Only the smaller parti-
cles (0.5 to 5 microns) reached the lower airways. Particle
stability was affected by the type of solution used. Concen-
trated solutions or hygroscopic solutions tended to take up
water from the environment, increase in size and were
deposited in the upper airways. Dilute solutions tend to
evaporate and become smaller, reducing the amount of mist
delivered to the patient, but reach deeper into the airways.
Cool-mist aerosols evaporate upon warming and decrease in
particle size, while warm-mist aerosols coalesce upon cooling,
and increase in particle size.
Miller (1973) evaluated the use of aerosolized antibiotics
and concluded that they are particularly effective against
resistant gram-negative organisms in patients with a major
problem of effective bronchial clearance. His evaluation was
substantiated by High et al. (1958), Rose et al. (1970),
Klastersky et al. (1974), and Feeley et al. (1974). Miller
(1973) concluded that the technique should be reserved for
patients with severe bronchopulmonary infection which fail to
respond to intensive bronchial hygiene and parenteral or oral
administration of antibiotics. Pine et al. (1970) and
Williams (1974) concluded from clinical studies that aerosol
antibiotic treatment was no more effective than parenterally
administered antibiotics.
Miller (1974) states that an antibiotic which is adminis-
tered as an aerosol should be one that has a potent topical
effect, is poorly absorbed to minimize systemic effects, and
is neither highly irritating nor allergenic. Dickie and
deGroot (1973) state that aerosol therapy may have specific
advantages over other methods of administration of the anti-
7biotic particularly if therapeutic levels of the antibiotic
can be achieved within airways and lung tissue without causing
deterioration in lung function. Prisgal (1956) concluded
that if antibiotics could be delivered to the lung tissue with-
out significant blood levels of the antibiotic then toxic
effects of these agents on other organs might be avoided.
Kanamycin has been demonstrated by High (1958) and
Bilodeau et al. (1966) to be safe and effective when adminis-
tered as an aerosol. Kanamycin was found by Bilodeau et al.
(1966) and Prokhorova II (1963) to be poorly absorbed into the
systemic circulation resulting in a decreased possibility of
auditory and renal toxicity. Prokhorova II (1968) showed
that with repeated nebulization, a high and accumulative
antibiotic level occurs in the lung tissue.
Lifschitz and Denning (1971) investigated three aspects
of the pharmacology of kanamycin aerosol. The three areas
were absorption, effect on airway resistance, and sputum
viscosity. Absorption of kanamycin from the tracheobronchial
airways was found to be so low that toxicity was not considered
a problem. Kanamycin had no effect upon airway resistance.
Sputum viscosity was reduced 52 percent following use of
kanamycin aerosol
.
Ayres et al. (1972) detected kanamycin in the urine of
patients following its delivery as an aerosol, but could not
detect levels in the venous or arterial serum, thus indicating
that small amounts are absorbed and cleared rapidly from the
bloodstream. Low serum levels of kanamycin have been reported
by Huang et al. (1959) and Bilodeau and Roy (1963) following
aerosol therapy.
Dickie and deGroot (1973) studied the ventilatory effects
of aerosolized kanamycin in patients with chronic lung disease
of varying etitology. Forced expiratory volume was decreased
slightly, but appeared physiologically insignificant in
regards to ventilatory function. Dickie and deGroot (1973)
concluded that insofar as its effect on the airway, kanamycin
would be an excellent therapeutic agent by aerosol.
Potter et al. (1965) found that kanamycin precipitates
with deoxynucleic acid from purulent sputum, and it may lower
sputum viscosity. The mucolytic effects of kanamycin was
confirmed by Lifschitz (1971) in patients with nonpurulent
sputum. Lifschitz (1971) concluded that the mucolytic effect
of kanamycin could enhance its clinical usefulness.
In man, the recommended dosage levels for aerosol use of
kanamycin varies from 100 mg per treatment (Matthews, et al .
1964) to 250 mg (Bilodeau, 1966) . In view of the evidence
that only a small fraction of an inhaled aerosol is deposited
in the lower respiratory tract, Spier et al. (1961) states
that the concentration should be adequate to assure thera-
peutic levels in the lung tissue.
Bolton (1977) states that antibiotic aerosols are irritat-
ing and may cause bronchial swelling and constriction. For
this reason, antibiotics are always used in conjunction with
bronchodilators, such as, isoproterenol or racemic epinephrine.
Walker and Stephen (1977) consider the elimination of the
total biomass of infective organisms the primary objective of
aerosol therapy and that the need for bronchodilators are
probably of little value in most causes of infectious
pneumonia.
Sheffner (1963) studied the in vitro effects of N-acetyl-
cysteine. Acetylcysteine is the N-acetyl derivative of the
amino acid cysteine. Acetylcysteine, a clear liquid with a
sulfur odor, is more stable than its parent compound but can be
inactivated by oxidation. In vitro efficiency is enhanced
by an alkaline pH. The mucolytic action of acetylcysteine is
related to the sulfhydryl group which reduces the viscosity of
mucoprotein solutions and bronchial secretions in vitro. The
free sulfhydryl group acts upon the disulfide bonds of
mucoprotein thereby reducing the viscosity of mucus (Sheffner,
1965)
.
Clinically, acetylcysteine has been shown to be thera-
peutically useful in the elimination of tracheobronchial
secretions as a result of its mucolytic properties by Reas
(1963) , Hurst et al. (1967) , Lieberman (1970) , and Utkin et al.
(1972) . Lieberman (1970) concludes that a 10 or 20 percent
solution is adequate for achieving a mucolytic effect. Reas
(1963) states that acetylcysteine delivered to the bronchial
airways by nebulization is adequate to reduce sputum
consistency.
Adverse side effects are seldom seen, but the danger of
acute bronchospasm in rare cases has been recognized by
Bernstein and Ausdenmore (1964) . Lieberman (1970) suggested
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that the bronchospasm is induced by bronchial irritation
arising from its hypertonicity. A 10 percent solution is
probably less irritating than a 20 percent solution. Kory
and Hirsch (1965) and Miller (1973) suggest the administration
of bronchodilators, such as, isoproterenol or racemic
epinephrine, preceding or accompanying the use of acetyl-
cysteine,
Jenkins and van Ovost (1974) successfully treated viral
pneumonia in the equine using intermittent positive-pressure
with a commercial respirator and nebulization therapy. Racemic
epinephrine and water were nebulized several times daily, in
conjunction, with positive-pressure therapy. A marked decrease
in congestion of the lungs and improved blood gas values were
noted following two days of therapy.
Bemis and Appel (1977) used antibiotic aerosol therapy and
demonstrated a reduction in bacterial density of Bordetella
bronchiseptica in dogs. Erythromycin, chloramphenicol, ampi-
cillin, tetracycline and tylosin given orally, and kanamycin
or gentamicin, given parenterally , were unable to reduce
bacterial numbers in the trachea and bronchi of infected dogs.
Clinical signs appeared to be related to bacterial numbers in
the bronchial airways. A properly administered aerosol
antibiotic regimen may reduce the bacterial density in the
trachea and bronchi, and thereby reduce the occurrence and
severity of clinical signs.
Lebedev et al. (1976) concluded that for group treat-
ment of respiratory disease in calves, and especially in
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acute bronchopneumonia, that the use of antibiotics in aerosol
form was very effective. The method was more economical in
time and materials, than parenteral injection.
Morel (1971) using two commercial preparations of
essential oils, applied as aerosols, showed they had an anti-
septic effect in the lungs. Promising results were obtained
in a stable of horses with influenza, a calfhouse with an
outbreak of pasteurellosis, and a herd of unthrifty pigs with
coughing.
Goldhamer et al. (1970) used a mucoevacuant solution
containing 0.125 percent tyloxapol, 2 percent sodium bicar-
bonate, and 5 percent glycerin in cats to study effects on
mucus flow. Significant increases in mucus flow rates occurred
at 20 and 60 minutes following exposure. In cats with res-
piratory pathology the amelioration of the reduced mucus flow
rate, accompanied by or caused by increased viscosity of the
mucus blanket, appeared to be amenable to agents which reduced
interfacial tension, reduced viscosity, and allowed mucus to
be moved in a normal fashion.
MATERIALS AND METHODS
Fifteen castrated male calves (4-Angus-Hereford cross,
5-Charolais cross, 2-Angus, 2-Hereford cross, and 2 Hereford)
averaging 213 kg. were utilized in this study. The animals
were part of a group of 105 mixed breed calves that were
received from central Texas. The total group was gathered
over a three day period by a commercial cattle buyer, and
transported to central Kansas on the fourth day. Processing
the day following receipt consisted of intranasal vaccination
for infectious bovine rhinotracheitis and parainfluenza,
vaccination for Clostridium chauvoei, septicum, novyi, and
sordelli, b deworming with thiabendazole, treatment for
ectoparasites using an organophosphate pour-on, branding and
dehorning.
Clinical cases were drawn from the total group as clinical
signs of bronchopneumonia developed over a two day period.
Selection of the animals on the farm was based upon labored
breathing, depression, anorexia, rectal temperature of 39.5 C
or greater, and/or nasal discharge. The calves exhibiting
clinical signs of bronchopneumonia were randomly divided into
a seven animal control group and an eight animal nebulized
(test) group.
All calves were given a general physical examination and
a Nasalgen, Jensen-Salsbery Laboratories, Kansas City, Mo.
b Electroid CSNS , Jensen-Salsbery Laboratories, Kansas
City, Mo.
c Thibenzole Cattle Wormer Paste 43%, Merck and Company,
Inc., Rathway, N.J.
d Co-Ral - Chemagro Corp., Kansas City, Mo.
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classified subjectively as to "Degree of Illness" (Hjerpe, 1975).
A numerical score of one was given to slightly ill or well
animals, two to moderately ill (moderately depressed, gaunt,
rough hair coat, acclerated respiratory rate) animals, and
three to severely ill (weak, very depressed, labored breathing)
animals. Each animal was evaluated daily throughout the
course of the trial as to "Degree of Illness."
Following the initial clinical examination of all animals,
an arterial blood sample was collected anaerobically from the
ventral coccygeal artery using a heparinized glass syringe.
Additional samples were collected daily in the same manner until
completion of the trial. The samples were analyzed for the
blood gas parameters of pH, P0
2
,
PC0
2 ,
total C0
2 ,
HC0
3 ,
and base
excess within two minutes of collection using a Corning pH
blood gas analyzer
.
e The analyzer was standardized at 0800
hours and 1300 hours daily with adjustments made for changes in
barometric pressure. Standardization and sample analysis were
made in accordance with the manufacturer's recommended proce-
dure.
A blood sample containing disodium ethylene-diamine-tetra
acetic acid (NaEDTA) for hematological studies was obtained
from the external jugular vein at the time of initial examina-
tion and on the day of discharge from the trial. Determina-
tions of packed cell volume (PCV) , hemoglobin content, total
plasma protein, plasma fibrinogen, and total white blood cell
count were made from each sample. PCV was determined using a
e Corning pH/Blood Gas Model 165, Scientific Instruments,
Corning Glass, Medford, Mass.
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microhematocrit tube. The hemoglobin content was calculated
through the use of the cyanomethemoglobin technique. Total
plasma protein levels were estimated through the use of a
hand refractometer. White blood cell totals were computed
using an electronic particle counter. g Fibrinogen assay was
determined by heating a microhematocrit tube filled with
blood containing EDTA for three minutes in a 50 degree centi-
grade waterbath. This will precipitate the fibrinogen which
is then removed by centrifugation in a high speed microhemato-
crit centrifuge for five minutes. Total protein in the
heated tube is then determined using a hand refractometer
.
The fibrinogen concentration is calculated by subtracting the
protein value in an unheated tube from the protein value in
the heated tube.
Bacterial specimens from the lower respiratory tract
were collected from calves number 1 and 12 using a trans-
tracheal aspiration technique. An area near the junction of
the proximal and middle one-third of the trachea was shaved
and surgically prepped. 3-5 cc of 2% lidocaine was infused
subcutaneously along the ventral surface of the trachea. A
skin incision approximately 2-3 centimeters in length was made
along the line of anesthetic infusion. An 8 gauge sterile
bleeding trochar was then introduced and directed between
adjacent tracheal rings into the lumen of the trachea. A
f Goldberg Refractometer , American Optical Corp.
,
Buffalo, N.Y.
g Coulter Counter model ZBI, Coulter Electronics Ind.
,
Hialeah, Fla.
h 2% Lidocaine HCL, Vitarine Co., New York, N.Y.
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polypropylene catheter1 was then directed through the trochar
and into the tracheal lumen. The trochar was removed prior to
the catheter being passed distally down the trachea. As soon
as the cough reflex was stimulated a 35 cc syringe containing
25 cc of sterile saline was attached to the catheter. The
saline was introduced into the lumen of the trachea and then
aspirated. If air was collected into the syringe, the syringe
was removed and the air was expelled prior to being reattached
to the catheter. Approximately 5 cc of aspirate was obtained
from each calf. Routine culture and antibiotic sensitivity
tests were performed on the transtracheal aspirations.
Eight calves assigned to the test group were prepared for
the installation of an indwelling tracheal catheter following
completion of the physical examination and blood sample collec-
tion. Catheterization was performed using the procedure for
transtracheal aspiration. The 55 centimeter polypropylene
catheter was replaced with a 20 centimeter length of polypro-
pylene catheter. The 5 centimeter exteriorized portion of the
catheter was sutured to the skin using 0.3 synthetic suture
material.-'
Aerosol therapy was conducted for five minutes duration
B.I.D. with the animal in standing restraint for each indivi-
dual in the test group. Five cc. of sterile saline followed
by five cc of air were flushed through the catheter prior to
each aerosol procedure to remove accumulated 'debris and mucus.
i Sovereign Polypropylene Catheter, 10 Fr., 55 cm.
Sherwood Medical Industries, St. Louis, Mo.
j Vetafil, Bengen R. , Dr. S. Jackson, Washington, D.C.
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Administration was accomplished by using a small air compressor
capable of producing 14 p.s.i. and 20 L/minute attached to a
k
commercial inline nebulizer. The aerosol solution consisted
of five cc of 20% N-acetyl-L-cysteine and five cc of kanamycin
sulfatem placed in the nebulizer vial. The aerosol solution
was estimated to be delivered at a rate of 3 cc per individual
treatment. Therapy was continued daily until the day of
discharge from the trial.
A commercial nebulizer was modified from its original
design for its adaptation to this trial. In order for the unit
to be attached to the indwelling tracheal catheter, a 15 centi-
meter section of patient supply hose replaced the exhalation
manifold. An inline reducer was attached to the patient supply
hose, which then could readily be inserted into the tracheal
catheter. Further modification of the original unit consisted
of occluding the patient supply inlet on the nebulizer mani-
fold by using a synthetic stopper. The nebulizer tube was
then connected to the synthetic stopper by means of a 14 gauge
disposable needle. This final adaptation was made in order
for any baffled solution to be returned to the aerosol
resevoir and to have a completely closed system.
Conventional treatment of bronchopneumonia as defined in
this trial consisted of antibacterial agents, B-complex
vitamins, palatable diet, and shelter. Conventional treatment
was initiated on day of the trial for all animals in the test.
k Lifeline Disposable, Model 1600, Monahgan, Littleton, Colo.
1 Mucomyst, Med Johnson Lab., Evansville, Ind.
m Kantrim 200 mg/cc, Bristol Lab., Syracuse, N.Y.
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Antibacterial agents used in the trial were oxytetracycline
at a dosage level of 11 mg/kg administered intravenously,
sulfadimethoxine sustained release boluses at a dosage level
of 137.5 mg/kg administered per os, sulfadimethoxine (12.5%
solutionp ) at a dosage level of 55 mg/kg administered intra-
venously, and Tylosinq at a dosage level of 13 mg/kg admini-
stered intravenously. Scheduling of the therapeutic regime is
outlined in Table 1. In Table 1, five calves (numbers 7, 8,
18, 19, and 20) on day were placed on the same treatment
regime as the remaining calves on day 1 of the trial. These
clinical cases were selected the day following receipt of the
first group due to delayed development of the clinical signs
of bronchopneumonia. This adjustment to the therapeutic
regime was utilized to standardize treatment.
Changes to different antibacterial agents in the treat-
ment regime were based upon a lack of response to treatment
as guided by rectal temperatures and/or "Degree of Illness."
A failure to respond as indicated by rectal temperature was
based upon declines of less than 1.2 degrees Centigrade, no
change, or an increase in rectal temperature. Failure of
response as dictated by "Degree of Illness" was failure to
change to a lower number group. A positive response to
treatment was interpreted as rectal temperature declines of
greater than 1.2 degrees Centigrade or a rectal temperature
n Liquamycin 50 mg/cc, Pfizer Inc., New York, N.Y.
o Albon SR boluses 12.5 gm/bolus, Hoffmann-LaRoche Inc.,
Nutley, N.J.
p Albon 12.5% Solution, Hoffmann-LaRoche Inc. , Nutley, N.J.
q Tylan 200, 200 mg/cc, Eli Lilly & Co., Indianapolis, In.
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less than 39.5 degrees Centigrade, and/or a change to a lower
number group based upon "Degree of Illness." If an animal
exhibited a positive response to treatment, the antibacterial
agent administered the day prior to the positive clinical
response was continued for 48 hours post-response. Clinical
response to treatment was reviewed daily and the treatment
regime was changed for all calves similiarly on day through
day 2 to establish a standard to evaluate clinical response.
Antibacterial agents were continued until the day of discharge
from the trial.
The need for supportive therapy was evaluated daily on
an individual animal basis. The clinical signs of anorexia
and refusal of water were used to determine the treatment, in
addition to the antibacterial agents, an animal would receive
daily. 10 cc of B-complex vitamins 17 administered intravenously
and/or .454 kg of a nutritional supplement3 administered per
os were used to combat nutritional deficits. 4-8 liters of
water administered via a stomach tube per os were used to
combat dehydration.
Rectal temperatures and clinical observations were
recorded daily for each calf throughout the test period.
Clinical observations were grouped for classification of
Severity of Illness. Severity of Illness was measured by
giving each calf a daily numerical score. One point was
assessed for each of the following subjective signs typical
of bronchopneumonia: depression, dyspnea, cough, epiphora,
r Multibex C, Eli Lilly & Co. , Indianapolis, In.
s Proleen T 20 powder, Diamond Laboratories, Des Moines, la,
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serous nasal discharge, mucopurulent nasal discharge, and
ptyalism.
Statistical evaluation was obtained by comparing values
of the subjective "Degree of Illness," the objective Severity
of Illness, and rectal temperatures in the test group to
those values in the control group. Daily values for the
arterial blood gases were statistically analyzed on the test
group and compared to the control group. Statistical compari-
son of the control and test group on day and day 3 of the
trial were made for hematocrit, hemoglobin content, total
plasma protein, plasma fibrinogen, and total white cell
levels.
RESULTS
Tracheal catheterization of the animals selected for the
test group was accomplished on the day of arrival at the
trial location. The time required for the catheterization
procedure on each calf was approximately five minutes. Slight
difficulty was noted in the passage of the catheter through
the 8 gauge trochar. Passing the catheter through the
trochar several times prior to the procedure, or removing 5 mm
of the proximal portion of the catheter facilitated the actual
placement of the catheter into the trachea. Complications
following this procedure were minimal throughout the course
of the trial in most of the recipients. Calves 1 through 4
experienced minor tracheal irritation as demonstrated by
slight coughing for approximately 60 minutes following place-
ment of the catheter into the trachea. A small area of
subcutaneous emphysema developed near the area of catheter
exit from the trachea in calf 8. The catheter placed in calf
1 was partially collapsed at the cutaneous exit point on the
day of removal. All catheters were covered with mucous at the
time of removal.
The transtracheal aspiration technique was performed on
day of the trial on calves 1 and 12. Both aspirates con-
tained an abundant growth of Pasteurella hemolytica. The
results of the sensitivity tests (Table 2) were obtained on
day 3 of the trial, and thus were of little value in the selec-
tion of an appropriate antibacterial agent (s) to be used in
the trial. The organism isolated was found to be resistant
20
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in vitro to four of the antibiotics generally administered
for the treatment of bovine bronchopneumonia- The isolate
from calf 12 was found to be resistant to tetracycline and
sulfadimethoxine, whereas tetracycline was found to be resis-
tant in calf 1. The organism was found to be sensitive to
kanamycin in both isolates. Oxytetracycline and sulfa-
dimethoxine were the primary antibacterial agents administered
from day through day 3 of the trial.
Rectal temperatures were obtained daily on each animal
throughout the trial (Table 3), except for calf 16 where a
temperature was not recorded on day 4. The mean daily tem-
peratures for the test and control groups were statistically
evaluated (Table 4) . The test group exhibited a significantly
(P>.05) lower rectal temperature on day 2 of the trial with a
mean of 39. 18 versus a mean of 39.71 for the control group. As a
group, the test animals maintained a mean rectal temperature of
less than 39.5 C from day 1 through the remainder of the trial,
whereas, the control group mean temperature was greater than
39.5 C throughout the course of the trial.
Temperature declines of greater than 1.2° C or to values
less than 39.5 C were interpreted as an indication of positive
response to treatment. Based on this classification of
response, calves 1, 2, 3, and 6 responded to treatment on day
1 of the trial and calves 5 and 8 on day 2. Calf 4 had a
temperature decline of
.
6° C from day to day 1 and stabilized
for the duration of the trial at values of 39.5° C to 39.6° C.
Calf 7 maintained temperatures of greater than 39.5° C throughout
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the duration of the trial. Calves 13 and 15 responded favor-
ably on day 1 of the trial, however, the rectal temperatures
rose to greater than 39.5° C on day 2 and remained elevated
until day 4 when a decline to less than 39.5 C occurred in
calf 13. A positive temperature decline occurred on day 2
of the trial in calf 16 and 20, however, the temperature of
calf 20 rose to 39.5° G on day 3. Calves 18 and 19 rectal
temperatures remained elevated throughout the course of the
trial.
Rectal temperature values on the day of discharge for
the test group would classify calves 1, 2, 3, 5, 6, and 8 as
having responded to treatment, and calves 4 and 7 as nonrespon-
sive to treatment. Values for the control group would
classify calves 12, 13, 16, and 20 as responsive to treatment
by the day of discharge and calves 15, 18, and 19 as non-
responsive.
"Degree of Illness," the subjective measurement of illness
in each individual, was recorded daily, and is tabulated in
Table 5. The test and control groups were compared statisti-
cally using the daily mean scores and are evaluated in Table 6.
The mean daily values of the control group were maintained at
a level of moderately ill, e.g. greater than 2, until the
day of discharge from the trial. The daily means of the test
group remained less than the moderately ill level throughout
the course of the trial with a range of 1.375 to 1.750.
Statistical evaluation of the daily mean "Degree of Illness"
indicated two days where significant differences (P>.05) were
noted, day 1 and day 2.
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The "Degree of Illness" was used as an indicator of
response to treatment. A decrease in numerical score was
interpreted as a positive response, whereas, no change in
score or an increase was interpreted as no response unless
the value was 1. Positive responses to treatment in the test
group were obtained in calf 3 on day 1, calves 6 and 8 on
day 2, and calf 5 on day 4. Positive responses in the control
group were seen in calves 19 and 20 on day 2, calf 16 on day 3
and calves 12, 13, and 15 on day 4. No response as indicated
by an increased value was determined for control group calves
12, 15, and 18 on day 1, and test group calf 4 on day 4 of
the trial. Calves considered slightly ill at the day of
discharge in the test group were numbers 1, 2, 3, 5, 6, and 8.
Those considered slightly ill in the control group were numbers
12, 13, 15, and 16. Calves considered moderately ill at dis-
charge were test group number 7 and control group numbers 19
and 20. Those severely ill at discharge were numbers 4 and 18
in the test and control group, respectively.
The observation of clinical signs, excluding temperature,
of bronchopneumonia were collectively evaluated as Severity
of Illness. This allowed for a daily objective assessment of
the clinical signs based on a numerical score in each animal
(Table 7) . Depression and serous nasal discharge were the most
frequently observed signs, however, a daily variation occurred
throughout the course of the trial. A distinct pattern of
alleviation of clinical signs could not be determined in either
group based upon the parameters of depression, dyspnea, cough,
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epiphora, serous nasal discharge, mucopurulent nasal discharge,
or ptyalism. However, by day 3 of the trial the calves in the
test group responding favorably to treatment as indicated by
temperature or "Degree of Illness" generally expressed a lower
numerical score than did the calves classified as nonresponsive.
This pattern could not be established for the control group.
The daily mean values established for each group were variable
and no significant differences were found during the course
of the trial (Table 8) . Mean daily values were less for the
test group than for the control group with the exception of day
of the trial.
EDTA samples for hematological studies were drawn on
day and the day of discharge from the trial. Samples
Obtained from calves 4 and 19 on the day of discharge clotted
prior to evaluation. The collected samples were analyzed for
the blood parameters of packed cell volume, hemoglobin con-
tent, total plasma protein, fibrinogen, and total white blood
cells (Tables 9 and 10) . Statistical comparisons were performed
on the data for the test group day versus the control group
day 0, test group day of discharge versus control group day of
discharge, control and treatment group day versus test group
day 3, and control and treatment group day versus control
group day 3 (Tables 11, 12, 13, and 14, respectively).
Mean packed cell volume (PCV) expressed as a percentage
were highest on day averaging 34.5 for the test group and
35.857 for the control group. The range for day being 27-41
for the test group and 26-40 for the control group. These
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values declined 5.143 for the test group to a level of 29.357
on the day of discharge as compared to a decline of 5.357 in
the control group to a level of 3 0.5 on the day of discharge.
The range was 22.5 to 34.0 and 20 to 38.0 for the test and
control groups, respectively, on the day of discharge. All
animals exhibited a decline in PCV during the course of the
trial except calves 13 and 16 which remained constant at 26
and 38, respectively. No significant differences were found
on the comparisons of the test and control groups on day or
on the test and control groups on the day of discharge (Tables
11 and 12)
.
Hemoglobin content expressed in grams % was higher in
the control group on day with a mean of 11.87 as compared
to a mean of 11.23 in the test group (Table 11), Comparison
on the day yalues to the day of discharge values on an
individual animal basis obtained variable results with some
animals increasing slightly while others declined (Tables 9
and 10) .
Mean total plasma protein levels expressed in grams %
decreased from 7.13 to 6.86 from day to the day of discharge
in the test group, and 6.83 to 6.75 over the same time span in
the control group (Tables 11 and 12) . Individual variance did
occur and a definite trend could not be established.
Mean fibrinogen levels expressed in milligram % were
greater for the test group on day than for the control group.
However, the levels were not of statistical significance.
Fibrinogen levels on day ranged from 100 to 800 in the test
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group with a mean of 487, whereas, the range of the control
group was 200 to 800 with a mean of 400. Four animals
(numbers 3, 4, 5, and 8) in the test group and only calf 20
in the control group were found to have fibrinogen levels
greater than 600 on day of the trial. The mean fibrinogen
levels were elevated by the day of discharge and were comparable
with a mean of 1000 for test group and 1017 for the control
group. Significant differences were not obtained on either
day or the day of discharge in the comparison of test to
control for each day.
Total white blood cells expressed as cells per cubic
millimeter rose slightly from a mean of 8887 to 9529 from day
to the day of discharge in the test group. No significant
differences were found between groups on day or on the day
of discharge.
The data obtained from the hematological studies for
day was statistically compared to the data obtained on the
day of discharge (Tables 13 and 14) . The test and control
groups were combined on day to provide a larger data base
to evaluate changes in hematological parameters. The test
group PCV and hemoglobin content had significantly decreased
(P>.05) from a mean of 35.13% to 29.36% and 11.55 gm% to
10.2 gm%, respectively. The fibrinogen levels were elevated
significantly (P >. 05) in both the test and control groups.
The parameters of PCV and hemoglobin content for the control
group, and total plasma protein and total white blood cell
count for both test and control groups were not statistically
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significant when day and day of discharge were compared.
The statistical analysis of the blood gas data is shown
on Tables 15-21. Comparisons are made only from day through
day 3 of the trial due to damage to the P0 2 membrane on the
blood gas analyzer. PO- and PCQ 2 values are expressed as
millimeters of Mercury (mmHg)
,
HCQ
3
and Total c0 2 values are
expressed as millimoles per liter. Base Excess values are
expressed as millequivalents per liter. Arterial samples
were not obtained on calves 3, 4, 1 t and 8 on day 0; calf 19
on day 1; calf 6 on day 2; and calves 3, 6, 7 , 8, 19, and 20
On day 3 of the trial due to failure to accurately locate the
coccygeal artery. Repeated sampling of the coccygeal artery
resulted in either a subcutaneous hematoma or thrombosis of
the coccygeal artery. The ability to obtain reliable arterial
blood samples, e.g. samples that were not mixed venous-arterial
samples, decreased as multiple arterial invasions progressed
throughout the trial.
The mean arterial pH values (Table 15) were comparable
in both the test and control groups during the course of the
trial. The range of the means for the test group was 7.468-
7,510, whereas, the control group range was 7.466-7.509.
Significant differences were not found.
P0
2
values were found to flucuate daily in the individual
calf and a pattern of response to either treatment could not
be established (Table 15). Samples for calf 4 day 1 (P0
2
119.2),
calf 8 day 2 (P0
2
110.2), calf 20 day 2 (P0
2
107,4), calf 12
day 3 (P0
2
107.3), calf 8 day 3 (P0
2
112.1) were not utilized
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in the statistical evaluation due to aerobic collection of the
sample. The mean arterial P0 ? value for the test group rose
significantly (P>.05) by day 2 of the trial (Table 17, Figure
1) while the P0 2 values of the control group remained basically
stable with a range of 62.583 to 68.467,
The comparison of the daily mean PC0 2 f HCCU, total CO-,
and base excess are shown on Tables 18-20 and Figures 2-5.
On day of the trial, the mean values for each parameter
were comparable, in both the test and control groups. Day 1
through day 3 of the trial revealed mean levels that were
greater in the test group than in the control group for all
parameters measured. Significant differences (P>.05) existed
for the blood gas parameters of HCO, and Total C0
?
between the
test and control groups on day 2 of the trial. The mean
values for the parameters of PC0
2
, HC03 , Total C0 2 , and Base
Excess decreased from the peak values found on day 1 for
both the test and control groups.
DISCUSSION
Pasteurella spp. are commonly incriminated as a causal
agent in bacterial bronchopneumonia in the bovine in the first
45 days postshipment (Jensen et a_l. 1976, Thomson et al.
1969) . Pasteurella hemolytica produces a fibrinous broncho-
pneumonia and pleuritis with prominent interlobular septa
and evident hemorrhage into the alveoli giving extensive and
confluent ventral consolidation of the pulmonary tissue
(Collier, 1968) . Histopathological findings of the bronchi
and bronchioles demonstrate lumens filled with exudate composed
of mucus, bacteria, neutrophils, macrophages, and blood
(Jensen et al. 1976)
.
Pasteurella organisms are not associated with apparently
healthy tissue of the lower respiratory tract in cattle
(Collier and Rossow 1964, and Lillie 1974). The association
of clinical bronchopneumonia in the calves on this trial and
isolation of Pasteurella hemolytica from the bronchial air-
ways would indicate that this organism was the primary
bacterial etiological agent. The use of transtracheal aspira-
tion technique provided a convenient method to obtain bacterial
cultures from the lower airways in cattle. The practicality of
using such a technique, however, is of limited value due to the
time interval between collection and receipt of the culture and
sensitivity data. Its use as a screening procedure to catalog
sensitivity data for future use has merit.
The selection of therapeutic antibacterial agents used in
this trial may have limited the response to treatment in both
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the test and control groups. Based on the in vitro sensitivity
results, oxytetracycline was of questionable value and
sulfadimethoxine may have been beneficial in some of the
cases. The addition of kanamycin sulfate to the aerosol
solution widened the spectrum of the therapeutic regime since
both isolates were sensitive.
Rectal temperatures were used as a direct and convenient
method to evaluate the response of the animals to treatment.
The rectal temperature maximum was based at a level of 39.5° C
with temperatures greater than this value considered as an
elevation above normal body temperature. The majority of
maximum temperatures were found on day of the trial and
subsequent temperatures were variable throughout the remainder
of the trial. Thomson et al. (1975) found that by day 3 of
illness the rectal temperatures were significantly higher in
animals with pneumonic pasteurellosis than those of normal
animals. The rectal temperatures of the test group declined
at a more rapid rate and were significantly lower (P>.05) by
day 2 of the trial than the temperatures in the control group.
Rectal temperatures on the day of discharge would indicate
that 75% of the test group and 57.1% of the control group met
the qualifications as responding to treatment.
The use of "Degree of Illness" provides a subjective means
to evaluate the clinical response of an animal to treatment.
It provides the observer a method to numerically score an
animal's progress and to evaluate the changes in severity of
the clinical condition. The test group .calves, as a group,
s
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improved significantly (P>.05) in attitude and clinical appear-
ance by days 1 and 2 of the trial. On the day of discharge
75% of the test group were classified as slightly ill or
well, 12.5% moderately ill, and 12.5% as severely ill, whereas,
values of 57.1, 28.6, and 14.3, respectively were classified
in the control group.
The clinical signs used to evaluate Severity of Illness
were depression, dyspnea, cough, epiphora, serous nasal dis-
charge, mucopurulent nasal discharge, and ptyalism. These
parameters varied in frequency and duration throughout the
course of the trial in all calves. Collier (1968) experi-
mentally induced pasteurella pneumonia in calves and evaluated
the clinical signs of anorexia, depressed attitude, cough, and
increased respiratory rate. Anorexia was found to persist
for an average of 3 days, depression for an average of 2.75
days, and cough for an average of 2.5 days in clinically
responsive calves. Due to the limitations placed on the
clinical signs in this trial the use of Severity of Illness as
a method to evaluate response to treatment was of limited value,
Hematological studies indicated no significant differences
between the test and control groups on the day of discharge.
Significant difference (P>.05) was noted between the combined
test and control group on day and the test group on day of
discharge for the parameters of PCV, Hg%, and fibrinogen and
the combined group on day and the control group on day of
discharge for the parameter of fibrinogen.
Packed cell volume and hemoglobin content decreased from
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levels of 35.1 and 11.6, respectively, on day of the trial
to levels of 29.3 and 10.2 in the test group and 30.5 and
10.7 in the control group on day of discharge. Kumar et al.
(1970) states that hematocrits increase during the course of
pneumonia due to a hypodynamic circulatory response and then
abate in convalescence because of expansion of blood volume.
Weiss (1977) found that following respiratory disease in
cattle the PCV decreases until approximately two weeks post-
recovery then returns to normal levels because of rehydration
and improvement of the nutrient state of the animal.
Total plasma protein did not decrease significantly from
levels of 7,00 gm% on day to levels of 6,85 and 6,75 in the
test and control groups, respectively. These levels are
greater than the ranges of 6.3 gm% found by Vestweber et al .
(1977) on calves with chronic bronchopneumonia and 6.5 gm%
found by Weiss (1977) in acutely ill feedlot steers. Wohler
(1972) reported a progressive depression of serum protein
levels for 1 week post-shipment. The levels found in this
trial might reflect a state of rehydration.
McSherry et al. (1970) reports that elevated fibrinogen
is a nonspecific indication of illness in cattle. During the
inflammatory response to pasteurella pneumonia fibrinogen
is coagulated into fibrin (Smith and Jones, 1972) . Fibrinogen
levels rose significantly in both the test and control groups
from a level of 447 mg% to approximately 1000 mg% by the day
of discharge. Thomson (1975) reports the normal bovine plasma
fibrinogen levels as 400-800 mg%
. Thomson (1975) states that
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plasma fibrinogen levels occur within 72 hours of a temperature
level of 40.0° C and are significantly higher than normal
animals by day 3-4 of illness with mean values of 1000-1100 mg%.
Thomson et al. (1969) suggests the use of plasma fibrinogen in
conjunction with body temperature to detect illness and to
identify animals with bacterial pneumonia.
White blood cell counts elevated slightly by the day of
discharge from levels of 8813/cmm to levels of 9529/cmm and
8950/cmm in the test and control groups, respectively. This
slight elevation is comparable to the changes found by
Weiss C1977) and Thomson et al, (1975) . Both test and con-
trol group levels are higher than the level of 8292/cmm
found in calves with chronic pneumonia by Vestweber et al .
(1977) .
The arterial blood gas evaluation was designed to
determine if differences exist between the test and control
groups during the course of the trial. Value ranges as
determined by other researchers are listed in Table 22.
The pH values were found to be consistently greater in both
the test and control animals than the values established as
normal. The P0
2
levels increased daily until day 3 in the
test animals and were significant (P>.05) on day 2 (82.1 mmHg)
of the trial. The control group PO~ levels tended to remain
depressed (<70 mmHg) . Base excess levels remained lower
through the course of the trial in the control group. Blood
HCCK and total C0
2
levels were found to be significantly (P>.05)
elevated on day 2 of the trial. Vestweber et al. (1977) reported
34
significant decreases in levels of blood P0 2 / HCO-j, and
total C0 2 in calves with chronic bronchopneumonia compared
to
normal calves.
The collection of arterial blood in the bovine to
evaluate daily clinical progress presents a technical problem.
The repeated daily coccygeal arterial puncture in this study
increased in difficulty as the time on trial lengthened.
Subcutaneous hematoma and failure to obtain samples limits
the usefulness of this technique as a diagnostic tool to
evaluate daily clinical progress in a group of pneumonia
animals. However, practical alternatives are few.
Pasteurella colonize in the bronchi, bronchioles, and
alveoli of infected animals (Jensen et al, 1976; Lillie, 1974;
and Thomson, 1974) , In pasteurellosis the number of bacteria
increase markedly as does mucus production (Lillie, 1974)
.
Nebulization techniques provide an alternate method with
which to adminster antibacterial agents in bacterial broncho-
pneumonia in cattle. The installation of antibacterial
agents directly to the area of greatest benefit, e.g. bronchi
and bronchiolar airways, could decrease the population of
organisms to a level sufficient to decrease the severity of
the disease. Recent work by Bemis and Appel (1977) has shown
that bacterial numbers were reduced significantly in the
respiratory tract when antibacterials were administered by
aerosols. The benefits of increased oxygen values to the
alveolar macrophage system has been reviewed by Veit (1976)
.
The use of mucolytic agents to liquefy bronchial secretions
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could further benefit the response of a compromised respira-
tory system.
Clinical signs attributable to bronchospasm e.g.
inspiratory and expiratory dyspnea, apprehension, flared
nares, and cyanosis, were not observed during the course of
nebulization treatment in this trial. The use of broncho-
dilators at this time, in conjunction with nebulization
therapy, appears to be unnecessary.
The use of nebulization therapy in the bovine provides
an alternate method to approach the treatment of acute
bacterial bronchopneumonia. A positive response to therapy
was observed during the course of the trial in the nebulized
animals. However, practical limitations do exist, such as
the time involved in placement of the indwelling tracheal
catheter, medication costs, and repeated handling of
clinically sick animals. The surgical procedure could be
eliminated by the introduction of a larger diameter catheter
through the nostrils with the medication deposited in the
retropharyngeal area. This could accomplish the same results
as with the tracheal catheter in that the turbinate are
by-passed thus depositing a larger volume of medication into
the tracheal airways.
.CONCLUSION
Nebulization therapy provides an alternate method for
the treatment of acute bacterial bronchopneumonia in cattle.
Disadvantages to the technique include the time involved in
the surgical placement of an indwelling tracheal catheter,
labor costs, medication costs, and the repeated handling of
clinically sick animals. Clinical cases of early acute
bronchopneumonia generally respond favorably to conventional
antibacterial and supportive therapy. A general recommenda-
tion would be to reserve nebulization therapy to animals
that fail to respond to conventional treatment by the second
or third day of clinical signs.
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TABLE 1
Therapeutic Regime Established for Control
and Test Groups
44
Calf
Day of trial
1
Test
1 AEX
2 AEX
3 AEX
4 AEX
5 AEX
6 AEFX
7 AEFX
8 AEFX
Control
12 AE
13 AE
15 AE
16 AE
18 AE
19 AEF
20 AEF
AEFX
AEFX
AEFX
AEFX
AEFX
ABCX
ABCX
ABCX
ABCX AX N.T.
ABCX AX N.T.
ABCX DX DX
ABCX DX DX
ABCX AX N.T.
AGX N.T. N.T.
ACX DX DX
ACX N.T. N.T.
AEF ABC CF N.T.
AEF ABC A N.T.
AEF ABC A C
AEF ABC A N.T.
AEF ABC A D
ABCEFG ACEFG D D
ABCE ACEFG D D
A - oxytetracycline
B - sulfadimethoxine bolus
C - sulfadimethoxine solution
D - tylosin
E - B-complex vitamins
F - nutritional supplement
G - water
X - aerosol therapy B.I.D.
N.T. - no treatment
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TABLE 2
The Results of the Kirby-Bauer Susceptibility Tests on Calf 1
and 12 Obtained from Transtracheal Aspirates
Antibacterial Agent Calf 1 Calf 2
Ampicillin — +
Cephalothin + +
Chloramphenicol + +
Erythromycin Int Int
Furazolidone (Furoxone) + +
Gentamicin + +
Kanamycin + +
Neomycin + +
Nitrofurazone (Furacin) + +
Penicillin -- +
Polymyxin B Int +
*Spectinomycin int Int
Streptomycin
*Sulfadimethoxine +
Tetracycline
Triple Sulfa
Trimethoprim/sulfamethoxazole + +
+ = sensitive
Int = intermediate
- = resistant
*Not measured by Kirby-Bauer Method
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TABLE 3
Rectal Temperatures (°C) of Steers with
Bronchopneumonia Taken at 24-Hour Intervals
Calf No.
Day of trial
1 2 3 4
Test
1 39.7 39.0 39.2 39.2 38.7
2 39.9 39.0 38.9 39.1 39.2
3 40.8 39.2 39.1 38.8 38.7
4 40.2 39.6 39.5 39.6 39.5
5 40.3 39.6 39.1 39.1 38.9
6 39.5 39.1 38.8
7 41.2 40.0 39.6 40,9 39.8
8 40.1 39.9 39.2 28.9
Control
12 41.1 40.4 40.5 40.1 38.6
13 40.0 38.9 39,7 39.7 39,2
15 39.8 39.1 39.8 39.8 39.5
16 40.1 39.9 39,2 38.9 N.E.
18 40.1 39.6 40.1 40.2 39.5
19 41.6 41.8 39.9 40.0 41.3
20 40.2 41.0 38,8 39.5 39.2
Calf 3 discharged on Day 2
Calf 8 discharged on Day 3
N.E. = not evaluated
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TABLE 5
"Degree of Illness" in Steers with Bronchopneumonia Assessed at
24-Hour Intervals During the Trial
Day of trial
Calf No. 1
Test
1 1 1
2 1 1
3 2 1
4 2 2
5 2 2
6 2 2
7 2 2
8 2 2
Control
12 1 2
13 2 2
15 1 2
16 2 2
18 2 3
19 3 3
20 3 3
1 1 1
1 1 1
1 1 1
2 2 3
2 2 1
1 X X
2 2 2
1 1 X
2 2 1
2 2 1
2 2 1
2 1 N.E
3 3 3
2 2 2
2 2 2
Calf 6 discharged Day 2
Calf 8 discharged Day 3
N.E. = not evaluated
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TABLE 7
Severity of Illness in Steers with Bronchopneumonia
Assessed at 24-Hour Intervals
Calf No.
Day of trial
1 2 3 4
Test
1 2 2 1 1 N.A.
2
2 2 3 2 1 1
3 2 2 1 1 N.A.
4 3 3 3 3 2
5 1 2 1 2 1
6 1 1 1 — —
7 2 2 4 4 N.A.
8 3 1 1 1 —
Control
12 2 2 2 2 2
13 2 2 3 2 1
15 2 3 4 5 1
16 1 1 1 1
18 2 2 2 1 2
19 2 3 3 3 N.A.
20 2 2 1 1 N.A.
Calf 6 discharged Day 2
Calf 8 discharged Day 3
1 Severity of Illness = the objective evaluation of clinical
signs based on a numerical value. One point was assessed
for each of the following clinical signs: depression,
dyspnea, cough, epiphora, serous nasal discharge, muco-
purulent nasal discharge, or ptyalism.
2 N.A. = no assessment
51
«
c
-1!
1
in
CD
H
cu
O
<«
C -H
c
CO O
•H g
u 3
id aj
a c
e a
ox;
rH c
CD <a o
O )-l
W •H CQ
J JJ
9
01 £.
•H 4J
E-i •P -H
a »
4J
CO 0J
U
1 0)
rH JJ
01 CO
in
CD r-l
c o
r-t U
rH V
M C
<U CJ
o
>.
*l
H
U
0)
>
<U
co
CO
o
c
(0
• • * • •
-H CO c/> CO Uj: in
HH • • • • •
•r-t 2 •A z ^ •Z
c
CP
•H
CO
<D
3
H
W
G
B 18
+J V
3 a
rH
O <M
<A n
X!
<
0)
c
rrj
«
(N
rM
o
i
M
en
s
CQ
CM
IX
o
2
idQ
a
3
O
u
U
CO
CM rsi CN
in
CN
VO CO
in r—
o in ^
o\ UD r^
U5 rH o\ in
CD
in
o r~ o
o in o
o co o
m
co
o
o
in
a
o
CJ U
rH C
•3 U
O -H O
•H CO
U CO «
a <u o
e
3
c
id
C
4->
G
U CP
a u
CU rd
TJ X.
« o
~ to
G 01 -rH
o c -a
CP
•O -H r-t
CD 01 Id
CO
id .
xi id
a
01 -H
G G
CP-H CD
-H rH rH
CO O 3
U
rH C 3
id G a
CJ -H O
•H S O
G O 3
•H rH £
rH rH
o o »
<u CD
CU U
.c id
c -U -C
o o
•H <4H CO
4J O -H
m
-a
3 £
rH O rH
id id id
> 0) co
14
cu o
> «-t 01
id
C
3
O
uCJ CU
CU 01 0)
-r-i 01 Ul
J3 CO
O oi »
oi id
cu id u
-C o
4J 01 J3
id a
n 3 -h
a
U] U CD
CO C
O J=
a tp
3
O
»
g
id oi
CU -H
C rH
a id
oi >,
>,hj
>, •
4J CU
H r-l
u o
CU o .
> oi -a a
cu
co
c
id
CU
E
c
o
-H
4-1
idH
>
0)
a
c
rd
cu
E
u
o
u
u
ai
>
CO
rH rH
<0
li-1 >O CD
• r-»O
in
-U O
id •
o
4-1
C *i
id id
CJ
-H 4J
WH C
-H Id
c o
-H VM
CO -H
c
4J CP
O -rl
G 01
n ii
CO D> a.
3
u u
X X
a u
CO CO
Z oi
a M
3 CP
CU
CJ u rH
c en
n) U
o 4J 4J
-H CO c
•M 41
•H 4J o
c
CP I H
•H
CO H CJ
m vo r^
52
TABLE 9
Hematological Values for the Test and Control Groups
on Day of the Trial
Calf No.
PCV
(%)
Hemoglobin
Content
(grams%)
Total Plasma
Protein
(grams%)
Fibrinogen
(milligram%)
Total
White Blood Cells
(cells/cubic millimeter)
Test
1 27.0 9.5 6.5 100 11,100
2 31.0 11.0 7.2 300 6,200
.3 41.0 11.0 6.8 800 9,800
4 32.0 12.4 7.6 600 7,000
5 39.0 12.8 6.9 800 11,600
6 32.0 10.3 7.0 400 7,300
7 38.0 12.0 7.8 300 12,500
8 36.0 11.2 7.2 600 5,600
Control
12 40.0 14.5 7.1 400 8,000
13 26.0 9.1 6.6 200 9,700
15 38.0 12.0 7.2 200 8,600
16 38.0 13.2 7.1 500 7,900
18 30.0 9.8 6.3 300 10,400
19 39.0 12.5 6.7 400 6,100
20 40.0 12.0 7.1 800 10,400
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TABLE 10
Hematological Values for the Test and Control Groups
on Day 3 of the Trial
PCV Hemoglobin Total Plasma Total
Calf No. (*) Content Protein Fibrinogen White Blood Cells
(grams*) (grams%) (milligrams*) (cells/cubic millimeter)
Test
1 25.0 9.8 7.0 800 8,200
2 28.0 9.5 6.9 700 8,900
3 34.0 11.0 6.5 1200 7,600
4
5 32.0 10.4 6.9 1100 14,300
e 22.5 8.2 6.5 900 7,100
7 32.0 11.3 7.2 1100 10,300
8 32.0 11.3 7.0 1200 10,300
Control
12 30.0 10.4 6.6 1100 6,700
13 26.0 9.0 6.6 900 13,900
15 32.0 11.0 6.5 900 7,800
16 38.0 14.3 7.1 900 10,400
18 20.0 7.0 6.3 900 6,500
19
20 37.0 12.5 7.4 1400 8.400
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TABLE 16
Daily P0
2
(mmHg) Values of Arterial Blood Samples
from the Test and Control Groups of
Steers with Bronchopneumonia
Calf No.
Day of Trial
1 2 3
Test
1 64.5 75.9 84.4 72.0
2 60.7 66.6 95.6 53.5
3 N.S. 84.3 73.9 N.S.
4 N.S. A.S. 85.5 N.S.
5 61.5 84.1 79.6 74.8
6 52.3 46.0 N.S. N.S.
7 N.S. 78.8 73.4 N.S.
8 N.S. 60.1 A.S. N.S.
Control
12 76.0 62.0 59.1 A.S.
13 57.3 78.4 75.1 67.7
15 / 87.1 84.2 67.9 69.2
16 58.8 68.4 58.9 63.1
18 62.4 58.7 61.2 A.S.
19 49.1 N.S. 53.3 N.S.
20 63.3 59.1 A.S. N.S.
N.S. = No sample
A.S. = Aerobic sample collection
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.Fifteen mixed breed castrated male calves averaging
213 kg were utilized in this trial. The calves were part of
a group of 105 calves shipped from central Texas to central
Kansas. Clinical cases were selected as signs of broncho-
pneumonia developed over a two day period. Fifteen cases
were randomly selected into an eight animal nebulized (test)
group and a seven animal control group.
Transtracheal aspirations demonstrated Pasteurella
hemolytica from the lower tracheal airways. Both groups were
treated with oxytetracycline and/or sulfadimethoxine. The
test group, in addition to parental therapy, were nebulized
for five minutes duration B.I.D. The nebulization solution
used was 20% N-acetyl-L-cysteine and 200 mg/cc kanamycin
sulfate administered with a small commercial nebulizer through
an indwelling tracheal catheter.
Response to treatment was determined by using rectal
temperatures and scoring as to "Degree of Illness." A
positive response to treatment was considered when the rectal
temperature declined by 1.2° C or to a level less than 39.5° C.
"Degree of Illness" was based upon a classification of 1-
slightly ill or well, 2-moderately ill, or 3-severely ill.
A decline to a lower numerical classification was interpreted
to be a positive response to treatment unless the value was 1.
Rectal temperatures of the test group declined signifi-
cantly (P>.05) by day 2 of the trial to a mean level of 39.18 C
compared to a mean level of 3 6.76° C for the control group.
By the day of discharge 75% of the test group and 56.1% of the
control group were classified as responding to treatment.
Statistical evaluation of the daily mean "Degree of
Illness" indicated days 1 and 2 were significantly (P>.05)
lower in the test group. Mean values were 1.625 on day 1
and 1.375 on day 2 in the test group, whereas, mean values
of 2.429 and 2.14 3 were found in the control group on day 1
and 2, respectively.
Blood samples drawn from the external jugular vein
mixed with EDTA and used for hematological studies. Samples
were obtained on day and the day of discharge from the
trial. On the day of discharge significant (P>.05) decreases
in PCV and hemoglobin content existed in the test group when
compared to day values. Significant (P>.05) increases in
fibrinogen levels had occurred in both the test and control
groups by the day of discharge.
Heparinized arterial samples were obtained daily from
the coccygeal artery. The blood gas parameters of pH, P0 2 ,
PCO , HCO.,, total C0~, and base excess were evaluated on
2 3 *
each sample. Significant difference (P>.05) existed between
the test and control groups on day 2 of the trial for the
values of P0
2
, HC0 3 , and total C0 2
-
The nebulized calves appeared to respond more rapidly to
the treatment of acute bacterial bronchopneumonia than did
the control group calves. Nebulization therapy provides an
alternate approach to the treatment of acute bronchopneumonia
in cattle.
